Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ:AGLE), a clinical-stage biotechnology company, announced its presentation at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. The presentation will occur on January 13 at 8:20 a.m. EST, led by CEO Anthony G. Quinn. A webcast of the event will be available for live and archived access. Aeglea focuses on developing therapeutics for rare metabolic diseases, with its lead candidate, pegzilarginase, in Phase 3 trials for Arginase 1 Deficiency, and AGLE-177 in Phase 1/2 trials for Homocystinuria.

AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will present at the 39^th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14.

Presentation Details

Date: Wednesday, January 13
Time: 8:20 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officer
Webcast: https://ir.aeglea.com/events-and-presentations/  

To access the live and archived webcasts, visit the Events & Presentations section of the Company's website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. A replay of the webcast will be available through the Company's website for 30 days thereafter.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a late clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301200439.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

When will Aeglea BioTherapeutics present at the J.P. Morgan Healthcare Conference?

Aeglea BioTherapeutics will present on January 13, 2021, at 8:20 a.m. EST.

Who will present for Aeglea at the J.P. Morgan Conference?

Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO, will present.

How can I access Aeglea's presentation at the J.P. Morgan Conference?

You can access the presentation live and via archive on Aeglea's website.

What is the stock symbol for Aeglea BioTherapeutics?

The stock symbol for Aeglea BioTherapeutics is AGLE.

What is the focus of Aeglea BioTherapeutics?

Aeglea BioTherapeutics focuses on developing human enzyme therapeutics for rare metabolic diseases.

What are Aeglea's leading product candidates?

Aeglea's lead product candidate, pegzilarginase, is in Phase 3 trials for Arginase 1 Deficiency.

What is AGLE-177?

AGLE-177 is a product candidate in a Phase 1/2 clinical trial for the treatment of Homocystinuria.